AzTrials
AzTrials

AdenocarcinomaBACAP-2NCT06128343

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

An observational study of Adenocarcinoma and Carcinoma, run by University Hospital, Toulouse at 8 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects. Read more about this study

Who is it for?
Ages 18 to 120 years
Conditions the study is for
Adenocarcinoma, Carcinoma, Neoplasms
What is being tested?
collection of biological samples
How many people
1,500 participants
Where
8 sitesFrance
Study dates
16 Nov 2023to 28 Feb 2035
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 120 years
  • All sexes
  • Adult, Older adult

Study population: Patients with a pancreatic adenocarcinoma proven cytologically or histologically without any treatment

Who may be able to join

  • Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
  • Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
  • Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

Who cannot join

  • Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
  • Pregnant or breastfeeding patient

Trial locations and contacts

8 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Barbara BOURNET, MD, PhD contact

(0)5 61 32 32 35 ext. +33

bournet.b@chu-toulouse.fr

Cindy CANIVET, PhD contact

(0)5 61 32 20 48 ext. +33

canivet.c@chu-toulouse.fr

8 sites in 1 country

France8 sites, 8 recruiting

  • Béthune hospital center

    Béthune, 62408

    Hélène VANDAMME, MD, hvandamme@ch-bethune.fr

    Not yet recruiting

  • Haut-Lévêque Hospital

    Bordeaux, 33604

    Véronique VENDRELY, MD, (0)5 57 62 33 13 ext. +33, veronique.vendrely@chu-bordeaux.fr

    Not yet recruiting

  • Huriez Hospital

    Lille, 59037

    Guillaume PIESSEN, MD, (0)3 20 44 44 07 ext. +33, Guillaume.PIESSEN@CHRU-LILLE.FR

    Stépahnie TRUANT, MD

    Not yet recruiting

  • Jean Mermoz private hosptila

    Lyon, 69008

    Bertrand NAPOLEON, MD, (0)4 78 75 67 43 ext. +33, dr.napoleon@wanadoo.fr

    Pascal ARTRU, MD

    Not yet recruiting

  • Saint Eloi Hospital

    Montpellier, 34295

    Eric ASSENAT, MD, e-assenat@chu-montpellier.fr

    Not yet recruiting

  • Regional Cancer Center From Montpellier

    Montpellier, 34298

    Nicolas FLORI, MD, (0)4 67 61 85 13 ext. +33, Nicolas.Flori@montpellier.unicancer.fr

    Not yet recruiting

  • PAU hospital

    Pau, 6400

    Philippe BARTHELEMY, Md, (0)5 59 72 67 72 ext. +33, philippe.berthelemy@ch-pau.fr

    Not yet recruiting

  • Rangueil hospital

    Toulouse, 31059

    Barbara BOURNET, MD, PhD, (0)5 61 32 32 35 ext. +33, bournet.b@chu-toulouse.fr

    Nicolas CARRERE, MD

    Recruiting

Other trials in France

About this study

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Read the detailed description

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).

The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:

  • the development of new diagnostic tools,
  • understanding the development of tumors of the pancreas
  • the development of new therapeutic targets
  • understanding the response to chemotherapy…
Being tested
collection of biological samples
Keywords
Adenocarcinoma, fine-needle aspiration, endoscopic ultrasonography, epidemiology, biobank, DNA tumors
Medical subject headings
Adenocarcinoma, Carcinoma, Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • collection of biological samplesOther

    Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Enrichment of prospective BACAP collection

    This collection is coming to enrich the prospective BACAP collection of fresh tumor tissue and/or fixed from the micro-biopsy under endoscopic ultrasound

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Nov 2023
  2. Study start16 Nov 2023
  3. Primary completion31 Jan 2035 (estimated)
  4. Study completion28 Feb 2035 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06128343
Sponsor's protocol ID
RC31/21/0191
Other IDs
2021-A01050-41
Acronym
BACAP-2
Status last verified
Mar 2026
First submitted
7 Nov 2023
Last updated
19 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Bardol T, Dujon AM, Taly V, Dunyach-Remy C, Lavigne JP, Costa-Silva B, Kurma K, Eslami-S Z, Cayrefourcq L, Canivet C, Muscari F, Bournet B, Alix-Panabieres C. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. BMC Cancer. 2024 Jun 10;24(1):709. doi: 10.1186/s12885-024-12463-8.

    PubMed 38853244

Questions about this trial

What is this clinical trial studying?

An observational study of Adenocarcinoma and Carcinoma, run by University Hospital, Toulouse at 8 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Barbara BOURNET, MD, PhD ((0)5 61 32 32 35 ext. +33, bournet.b@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Enrichment of prospective BACAP collection (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06128343, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in